Quest LaboratoriesNSE:QUESTLAB -0.10%44 Debt-to-EBITDA is 0.70 as of Mar. 2026, which is 40% above its 10-year median of 0.50. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 7 warning signs investors should review. Among 686 Drug Manufacturers companies, Quest Laboratories ranks worse than 65.31% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Quest Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:QUESTLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.32 Med: 0.5 Max: 2.07
Current: 1.03
During the past 6 years, the highest Debt-to-EBITDA Ratio of Quest Laboratories was 2.07. The lowest was 0.32. And the median was 0.50.
NSE:QUESTLAB's Debt-to-EBITDA is ranked worse than 65.31% of 686
companies
in the Drug Manufacturers industry
Industry Median: 1.685
vs NSE:QUESTLAB: 1.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Quest Laboratories Debt-to-EBITDA Related Terms
Quest Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Quest Laboratories (NSE:QUESTLAB) has a Debt-to-EBITDA of 0.70 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Quest Laboratories. This is 40% above median its historical median of 0.50. Over the past decade, Quest Laboratories' Debt-to-EBITDA has ranged from 0.32 to 2.07. According to the industry distribution chart, Quest Laboratories ranks #448 out of 686 companies in the Drug Manufacturers industry, placing it in the top 65.3%.
Is Quest Laboratories' Debt-to-EBITDA too high?
Quest Laboratories' current Debt-to-EBITDA of 0.70 is 40% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 2.07. The Drug Manufacturers industry median Debt-to-EBITDA is 1.69. Quest Laboratories' value of 0.70 is 58.5% below this industry median. Based on the distribution chart, Quest Laboratories ranks #448 out of 686 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #448 out of 686 companies for Debt-to-EBITDA. This places Quest Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 1.69. Quest Laboratories' value of 0.70 is 58.5% below this benchmark. Historically, Quest Laboratories' own Debt-to-EBITDA has ranged from 0.32 to 2.07 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 1.69, Quest Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.69, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current Debt-to-EBITDA of 0.70 is 58.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Quest Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current Debt-to-EBITDA is 0.70, which is 40% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Debt-to-EBITDA of 0.70. The current Debt-to-EBITDA is 0.70, which is 40% above median its 10-year median of 0.50 and 58.5% below the Drug Manufacturers industry median of 1.69. Quest Laboratories' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Debt-to-EBITDA is 0.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
